NEW YORK (Reuters) -Health and wellness companies are embracing weight-loss drugs and building offerings around them in an ...

Popular obesity and diabetes drugs called GLP-1 medications may have added benefits, with a new study finding they helped ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

While they share similarities, there are differences, particularly between the drugs semaglutide and tirzepatide.

The weight-loss drug revolution is reshaping the health and wellness industry, forcing companies to adapt or face the same ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...